Dendreon Corporation Files Registration Statement for the Public Offering of 2,500,000 Shares of Common Stock.Business Editors/Health & Medical Writers SEATTLE--(BW HealthWire)--Oct. 11, 2000 Dendreon Corporation (Nasdaq:DNDN) today announced that it has filed with the Securities and Exchange Commission a registration statement relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc a proposed public offering of 2,500,000 shares of common stock. The offering will be lead-managed by Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated, and co-managed by SG Cowen Securities Corporation and Pacific Growth Equities, Inc. Dendreon, based in Seattle, Washington, is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon is focused on the development of novel therapeutic vaccines for the treatment of cancer using proprietary antigen discovery, antigen engineering and dendritic cell dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. technologies, including a prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. vaccine, Provenge(TM), which is in Phase III clinical trials, and a therapeutic vaccines for B-cell malignancies, Mylovenge(TM), which is in Phase II trials. A copy of the preliminary prospectus Preliminary Prospectus A first draft registration statement filed by a firm prior to proceeding with an initial public offering of securities. The document, filed with the Securities & Exchange Commission, is intended to provide pertinent information to prospective shareholders relating to these securities may be obtained, when available, from Prudential Securities, 111 8th Avenue, 5th Floor, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York 10011, phone: 212/776-8172, fax: 212/776-8144. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws or any such state or jurisdiction. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion